Modern solutions based on molecular DNA methodologies, which provide low-, medium- and high-resolution typing, enabling the identification of HLA antigens in the donor and potential recipient, the determination of their genetic specificity, and the assessment of donor-recipient compatibility based on genetic profiles. Equipment and specialised reagents for conducting HLA typing in related and unrelated bone marrow/haematopoietic stem cell and solid organ transplants.
The initial assessment of patients awaiting bone marrow or solid organ transplantation must include screening for pre-existing donor-specific antibodies and a lymphocytotoxicity test (cross-match test with donor lymphocytes, cross-match procedure). A comprehensive range of solutions for screening and cross-matching – specialised reagents, inverted microscopy, flow cytometry, and multiplex testing based on xMap Luminex technology from One Lambda Inc., the global leader in this field. The above solutions enable the prediction of immune compatibility between the recipient and a potential donor, the prediction of early rejection following transplantation, and the assurance of graft viability. They also enable post-transplant monitoring of the presence and progression of immune rejection of the organ.
A solution for monitoring the narrow therapeutic range of immunosuppressants using liquid chromatography with tandem mass spectrometry detection to minimise the risks of graft loss and organ rejection. HPLC/MS/MS systems, which ensure high specificity and sensitivity of analysis and allow for the simultaneous monitoring of several drugs.
Gel-based technology for the detection of erythrocyte antigens and antibodies, and automated analysers that will enable the phenotyping of donors and recipients and the individual matching of up to 10 blood antigens and blood components. Technologies to reduce the immunohaematological burden on patients and minimise the risk of haemolysis during transfusion.
Cutting-edge technologies for the inactivation of pathogens in blood cells – including both bacteria and viruses – which effectively block the replication, transcription and repair of pathogen DNA and RNA. These technologies are recommended for use by the European Association of Transfusion Medicine.
Systems for the automated processing of red blood cells (freezing, thawing and washing), which enable the collection of safe blood components in accordance with international standards and protocols. Solutions for establishing a blood bank for rare phenotypes.
Equipment for the collection of blood components and peripheral blood haematopoietic stem cells from the bloodstream for subsequent transplantation in accordance with EDQM standards.
Equipment for carrying out therapeutic plasmapheresis, plasma exchange and other therapeutic procedures in accordance with European transplantation protocols.